SEARCH

SEARCH BY CITATION

References

  • 1
    Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492497.
  • 2
    Sulkowski M, Thomas D. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138: 197207.
  • 3
    Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. HEPATOLOGY 1999; 30: 10541058.
  • 4
    Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: meta-analysis. Clin Infect Dis 2001; 33: 562569.
  • 5
    Rullier A, Trimoulet P, Neau D, Bernard PH, Foucher J, Lacoste D, et al. Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients. Hum Pathol 2004; 35: 10881094.
  • 6
    Cooper CL, Cameron DW. Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection. Clin Infect Dis 2002; 35: 873879.
  • 7
    Torriani FJ, Rodríguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438450.
  • 8
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451459.
  • 9
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004; 292: 28392848.
  • 10
    Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: 2736.
  • 11
    Data sheet of Pegasys. F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • 12
    Data sheet of Pegintron. Schering Corp., Kenilworth, NJ.
  • 13
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005; 10: 309317.
  • 14
    Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Antivir Ther 2007; 12: 469476.
  • 15
    Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007; 14: 228238.
  • 16
    Márquez-Peiró JF, Valero-Alcocer VE, Llopis-González A, Pérez-Peiró C. Effectiveness of peginterferon alpha-2a or -2b plus ribavirin in naïve patients with hepatitis C infection. Enferm Infecc Microbiol Clin 2008; 26: 135140.
  • 17
    Almasio PL, Cavalletto L, Chemello L, Craxi A, Fahrbach K, Frame D, et al.; for the HCV Meta-Analysis Working Group. Efficacy of PEG-IFN alfa-2b vs PEG-IFN alfa-2a + ribavirin regimens in treatment-naive chronic HCV patients: a cumulative meta-analysis of retrospective data from 6 clinical sites. 56th annual meeting of the American Association for the Study of Liver Diseases (56th AASLD). November 2005: San Francisco, CA [Abstract 62599].
  • 18
    Poordad F, Tran TT, Ayoub W, Patel Y, Chan L. A comparison of sustained viral response in patients with chronic hepatitis C virus (HCV) treated with peginterferon alfa-2a (peg2a) versus peginterferon alfa-2b (peg2b) and ribavirin. 70th Annual Scientific Meeting of the ACG 2005. October 2005: Honolulu, HI [Abstract 325].
  • 19
    Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, et al. A randomised trial to compare the pharmacodynamic, and antiviral effects peginterferon alfa-2b and peginterferon alfa2a in patients with chronic hepatitis C (Compare). J Hepatol 2006; 45: 204213.
  • 20
    Berenguer J, Gonzalez J, Lopez Aldeguer J, Von-Wichman MA, Quereda C, Pulido F, et al. Peginterferon alfa-2a plus ribavirin vs peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (47th ICAAC). September 2007: Chicago [Abstract V-1897].
  • 21
    Sulkowski M, Lawitz E, Shiffman ML, Muir AJ, Galler G, McCone J, et al. Final results of the IDEAL (individualized dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy Phase IIIB study. 43th European Association for the Study of the Liver (43th EASL). April 2008: Milan, Italy [Abstract LB-991].
  • 22
    Ascione A, De Luca M, Tartaglione MT, Lampasi F, Galeota Lanza A, Picciotto FP, et al. Peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. 43th European Association for the Study of the Liver (43th EASL). April 2008: Milan, Italy [Abstract LB-990].
  • 23
    Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999; 37: 26252630.
  • 24
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372374.
  • 25
    International Statistical Classification of Diseases and Related Health Problems, 1989 Revision. Geneva, Switzerland: World Health Organization; 1992.
  • 26
    Doménech JM. Bioestadística. Metodos estadísticos para investigadores. Barcelona, Spain: E Herder; 1980, 126 pp.
  • 27
    Dore GJ, Torriani FJ, Rodriguez-Torres M, Bräu N, Sulkowski M, Lamoglia RS, et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 2007; 21: 15551559.
  • 28
    Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005; 54: 10141020.
  • 29
    Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, et al. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther 2007; 12: 12251235.
  • 30
    Fuster D, Huertas JA, Gómez G, Solà R, González García J, et al.. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Antivir Ther 2005; 10: 841847.
  • 31
    Núñez M, Ocampo A, Aguirrebengoa K, Cervantes M, Pascual A, Echeverria S, et al; PRESCO Team. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008; 15: 363369.
  • 32
    Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al; WIN-R Study Group. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. HEPATOLOGY 2007; 46: 971981.
  • 33
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 34
    Manss MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 35
    Torriani F, Ribeiro R, Gilbert T, Schrenk UM, Clauson M, Pacheco DM, et al. HCV and HIV dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188: 14981507.
  • 36
    Soriano V, Nunez M, Camino N, Maida I, Barreiro P, Romero M, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004; 9: 505509.
  • 37
    Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, et al. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J Acquir Immune Defic Syndr 2007; 44: 174178.